Is LVCE or MRK a better dividend investment in 2026?

LVCE currently yields 32258.06% with a 5% 5-year dividend growth rate. MRK yields 3.25% with 8.2% growth. The better choice depends on your goal: LVCE offers higher current income.

What is the dividend yield difference between LVCE and MRK?

LVCE has a forward dividend yield of 32258.06% ($2.00/share annually). MRK yields 3.25% ($3.08/share annually). The yield gap is 32254.81 percentage points.

Home › Compare › LVCE vs MRK

LVCE vs MRK: Dividend Comparison 2026

LVCE yields 32258.06% · MRK yields 3.25%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 LVCE wins by $6.080919504444377e+21M in total portfolio value

INVESTMENT

TIME HORIZON10 years

LVCE

● Live price

32258.06%

Share price

$0.01

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$6.080919504444377e+21M

Annual income

$6,044,061,792,929,915,000,000,000,000.00

Full LVCE calculator →

MRK

Merck & Co. Inc.

● Live price

3.25%

Share price

$94.80

Annual div

$3.08

5Y div CAGR

8.2%

Payout ratio

42%

After 10 yrs · $10,000 · DRIP

Portfolio value

$30.7K

Annual income

$950.29

Full MRK calculator →

Portfolio growth — LVCE vs MRK

📍 LVCE pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	LVCE	MRK
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, LVCE + MRK cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

LVCE pays

MRK pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

LVCE

Annual income on $10K today (after 15% tax)

$2,741,935.48/yr

After 10yr DRIP, annual income (after tax)

$5,137,452,523,990,427,000,000,000,000.00/yr

MRK

Annual income on $10K today (after 15% tax)

$276.16/yr

After 10yr DRIP, annual income (after tax)

$807.75/yr

At 15% tax rate, LVCE beats the other by $5,137,452,523,990,427,000,000,000,000.00/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of LVCE + MRK for your $10,000?

LVCE: 50%MRK: 50%

100% MRK50/50100% LVCE

Portfolio after 10yr

$3.0404597522221886e+21M

Annual income

$3,022,030,896,464,957,500,000,000,000.00/yr

Blended yield

99.39%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

LVCE

No analyst data

MRK

Analyst Ratings

Buy

Hold

Sell

Consensus: Buy

Price Target

$128.54

+35.6% upside vs current

Range: $100.00 — $150.00

Altman Z

4.0

Piotroski

6/9

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

LVCE buys

MRK buys

No recent congressional trades found for LVCE or MRK in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricLVCEMRK

Forward yield	32258.06% ✓	3.25%
Annual dividend / share	$2.00	$3.08 ✓
Payout ratio	50%	42% ✓
1-year div growth	0%	5.5% ✓
5-year div CAGR	0%	8.2% ✓
Portfolio after 10y	$6.080919504444377e+21M	$30.7K ✓
Annual income after 10y	$6,044,061,792,929,915,000,000,000,000.00 ✓	$950.29
Total dividends collected	$6.078495418304981e+21M	$6.1K ✓
Payment frequency	quarterly	quarterly
Sector	Stock	Healthcare

Year-by-year: LVCE vs MRK ($10,000, DRIP)

Year	LVCE Portfolio	LVCE Income/yr	MRK Portfolio	MRK Income/yr	Gap
1← crossover	$3,236,506	$3,225,806.45	$11,192	$351.54	+$3.23M → LVCE
2	$979,196,089	$975,733,027.32	$12,524	$392.70	+$979.18M → LVCE
3	$276,940,574,299	$275,892,834,483.63	$14,015	$438.65	+$276940.56M → LVCE
4	$73,220,843,454,915	$72,924,517,040,414.64	$15,682	$489.96	+$73220843.44M → LVCE
5	$18,097,646,590,830,880	$18,019,300,288,334,120.00	$17,547	$547.23	+$18097646590.81M → LVCE
6	$4,181,742,514,252,880,400	$4,162,378,032,400,691,000.00	$19,632	$611.16	+$4181742514252.86M → LVCE
7	$903,336,272,998,417,400,000	$898,861,808,508,166,900,000.00	$21,963	$682.53	+$903336272998417.38M → LVCE
8	$182,435,095,891,060,850,000,000	$181,468,526,078,952,540,000,000.00	$24,571	$762.18	+$182435095891060864.00M → LVCE
9	$34,446,459,359,310,920,000,000,000	$34,251,253,806,707,490,000,000,000.00	$27,486	$851.08	+$34446459359310917632.00M → LVCE
10	$6,080,919,504,444,377,000,000,000,000	$6,044,061,792,929,915,000,000,000,000.00	$30,745	$950.29	+$6.080919504444377e+21M → LVCE

LVCE vs MRK: Complete Analysis 2026

LVCE — Stock

LiveCare, Inc. focuses on addressing the diabetic epidemic and other chronic diseases through state-of-the-art technologies and a human-touch approach. The company is a real-time health, analytics, service, and monitoring company that provides persons with type II diabetes with solutions. The company was incorporated in 2018 and is based in Venice, Florida.

Full LVCE Calculator →

MRK — Healthcare

Merck is a Dividend Aristocrat with 14+ consecutive years of increases. Keytruda (pembrolizumab) is the world's best-selling cancer drug and drives exceptional cash generation. The company's oncology and vaccines pipeline provides long-term growth visibility beyond the Keytruda patent cliff in the 2030s.

Full MRK Calculator →

📬

Get this LVCE vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

LVCE vs SCHD LVCE vs JEPI LVCE vs O LVCE vs KO LVCE vs MAIN LVCE vs JNJ LVCE vs ABBV LVCE vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.